Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease

European Heart Journal

Volumn 34, Issue 21, 2013, Pages 1587-1596

  Krämer, Johannes ^a   Niemann, Markus ^a   Liu, Dan ^a   Hu, Kai ^a   MacHann, Wolfram ^a   Beer, Meinrad ^b   Wanner, Christoph ^a   Ertl, Georg ^a   Weidemann, Frank ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Echocardiography; Fabry disease; Magnetic resonance imaging; Myocardial fibrosis; Speckle tracking

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FABRY DISEASE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HUMAN; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPECKLE TRACKING; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ULTRASOUND SCANNER;

ECHOCARDIOGRAPHY; FABRY DISEASE; MAGNETIC RESONANCE IMAGING; MYOCARDIAL FIBROSIS; SPECKLE TRACKING;

CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FABRY DISEASE; FEMALE; FIBROSIS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MYOCARDIUM; ROC CURVE; STRESS, PHYSIOLOGICAL; SYSTOLE;

EID: 84878877932     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht098     Document Type: Article

References (23)

1. Desnick R, Innou Y, Eng C. Fabry disease. Alpha galactosidase A deficiency. In: Scriver C, Beaudet A, Sly W, Valle D (eds), The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill; 1995, p2741-2784.
2. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H. An atypical variant of Fabry disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:228-293.
3. Weidemann F, Breunig F, Beer M, Sandstede J, Stö rk S, VoelkerW, Ertl G, Knoll A, Wanner C, Strotmann JM. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005;26:1221-1227.
4. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 2006;8:479-482.
5. Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Yoshimitsu M, Higuchi K, Nakao S. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 2008; 51:50-59.
6. Teraguchi H, Tekenaka T, Yoshida A, Taguchi S, Ninomiya K, Yoshida H, Horinouchi M, Yonezawa S, Nakao S, Minagoe S, Tei S. End-stage cardiac manifestations and autopsy findings in patients with cardiac Fabry disease. J Cardiol 2004;43:98-99.
7. MacDermot K, Holmes A, Miners A. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-807.
8. MacDermot K, Holmes A, Miners A. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-760.
9. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance imaging in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151-2155.
10. Perk G, Tunick PA, Kronzon I. Non-Doppler two-dimensional strain imaging by echocardiography-from technical considerations to clinical applications. J Am Soc Echocardiogr 2007;20:234-243.
11. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-133.
12. Kosmala W, Plaksej R, Strotmann JM, Weigel C, Herrmann S, Niemann M, Mende A, Stö rk S, Angermann CE, Wagner JA, Weidemann F. Progression of left ventricular functional abnormalities in hypertensive patients with heart failure: an ultrasonic two-dimensional speckle tracking study. J Am Soc Echocardiogr 2008;21:1309-1317.
13. Rosen BD, Edvardsen T, Lai S, Castillo E, Pan L, Jerosch-Herold M, Sinha S, Kronmal R, Arnett D, Crouse JR 3rd, Heckbert SR, Bluemke DA, Lima JA. Left ventricular concentric remodeling is associated with decreased global and regional systolic function: the Multi-Ethnic Study of Atherosclerosis. Circulation 2005; 112:984-991.
14. Edvardsen T, Rosen BD, Pan L, Jerosch-Herold M, Lai S, Hundley WG, Sinha S, Kronmal RA, Bluemke DA, Lima JA. Regional diastolic dysfunction in individuals with left ventricular hypertrophy measured by tagged magnetic resonance imaging-the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2006; 151:109-114.
15. Fernandes VRS, Polak JF, Edvardsen T, Carvalho B, Gomes A, Bluemke DA, Nasir K, O'Leary DH, Lima JA. Subclinical Atherosclerosis and incipient regional myocardial dysfunction in asymptomatic individuals. The Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006;47:2420-2428.
16. Weidemann F, Niemann M, Warnock DG, Ertl G, Wanner C. The Fabry cardiomyopathy: models for the cardiologist. Annu Rev Med 2011;62:59-67.
17. Linhart A, Lubanda JC, Palecek T, Bultas J, Karetová D, Ledvinovà J, Elleder M, Aschermann M. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 2001;24(Suppl 2):75-83.
18. Weidemann F, Niemann M, Herrmann S, kung M, Stö rk S, Waller C, Beer M, Breunig F, Wanner C, Voelker W, Ertl G, Binjens B, Strotmann JM. A new echocardiographic approach for the detection of non-ischemic fibrosis in hypertrophic myocardium. Eur Heart J 2007;28:3020-3026.
19. Weidemann F, Strotmann JM. Use of tissue Doppler imaging to identify and manage systemic diseases. Clin Res Cardiol 2008;97:65-73.
20. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-1301.
21. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003;107: 1987-1984.
22. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stö rk S, Voelker W, Ertl G,Wanner C, Strotmann J. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119:524-529.
23. Risum N, Ali S, Olsen NT, Jons C, Khouri MG, Lauridsen TK, Samad Z, Velazquez EJ, Sogaard P, Kisslo J. Variability of global left ventricular deformation analysis using vendor dependent and independent two-dimensional speckle tracking software in adults. J Am Soc Echocardiogr 2012;25:1195-1203